TCD 717

Drug Profile

TCD 717

Alternative Names: TCD-717

Latest Information Update: 23 Mar 2016

Price : $50

At a glance

  • Originator TCD Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action CHKA protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 23 Mar 2016 No recent reports on development identified - Phase-I for Solid tumours (Late-stage disease) in USA (IV)
  • 28 Feb 2014 TCD Pharma completes a phase I trial in Solid tumours (Late-stage disease) in USA (NCT01215864)
  • 31 Jan 2011 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top